Major Depressive Disorder Research Reagents

BDNF — Reduced BDNF-TrkB signaling in hippocampus and prefrontal cortex is a central feature of MDD pathophysiology. Anti-BDNF antibodies and recombinant BDNF proteins support neuroplasticity research and antidepressant mechanism-of-action studies.
→ Browse BDNF antibodies & proteins

Serotonin Transporter (SLC6A4/SERT) — SERT mediates serotonin reuptake and is the primary target of SSRIs. Anti-SERT antibodies enable transporter expression profiling, occupancy studies, and pharmacogenomic research.
→ Browse serotonin pathway antibodies

IDO1 (Indoleamine 2,3-Dioxygenase) — IDO1-mediated tryptophan-kynurenine pathway activation links neuroinflammation to depression through serotonin depletion and neurotoxic quinolinic acid production. Anti-IDO1 antibodies support kynurenine pathway studies in inflammation-driven depression.
→ Browse IDO1 antibodies & proteins

1. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299-2312. DOI

2. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72. DOI

3. Berman RM, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. DOI

4. Dantzer R, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56. DOI